Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22197991 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL24508761 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL12282003 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL12281920 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL12070762 | 0.97 | KDM4E (0.75) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL12014973 | 0.93 | KDM4E (0.70) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL2952645 | 0.92 | — | — | |
| SCHEMBL14739904 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL14740196 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL1900654 | 0.89 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125790-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2021231778-A1 | CORONAVIRUS PROTEASE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021127283-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264490-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-8722732-B2 | Oligomer-calcimimetic conjugates and related compounds | NEKTAR THERAPEUTICS (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120238621-A1 | Oligomer-Calcimimetic Conjugates and Related Compounds | NEKTAR THERAPEUTICS (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | KDM4E 935/4885MAPK1 3746/4885HIF1A 1784/4885 |
| US-20120238621-A1 | Oligomer-Calcimimetic Conjugates and Related Compounds | CALCR, CALCB, CALCA | KDM4E 4830/4885MAPK1 4573/4885HIF1A 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.